Werewolf Therapeutics Stock Performance
| HOWL Stock | USD 1.12 0.00 0.00% |
The firm maintains a market beta of 1.22, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Werewolf Therapeutics will likely underperform. At this point, Werewolf Therapeutics has a negative expected return of -0.43%. Please make sure to check out Werewolf Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Werewolf Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Werewolf Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
1 | Acquisition by Daniel Hicklin of 295500 shares of Werewolf Therapeutics subject to Rule 16b-3 | 12/26/2024 |
2 | Acquisition by Daniel Hicklin of 185652 shares of Werewolf Therapeutics at 1.56 subject to Rule 16b-3 | 01/02/2025 |
3 | Acquisition by Chulani Karunatilake of 103600 shares of Werewolf Therapeutics subject to Rule 16b-3 | 01/03/2025 |
4 | Acquisition by Daniel Hicklin of 592690 shares of Werewolf Therapeutics at 1.56 subject to Rule 16b-3 | 01/06/2025 |
5 | Werewolf Therapeutics stock hits 52-week low at 1.37 - Investing.com | 01/10/2025 |
6 | Werewolf Therapeutics Price Target Lowered to 4.00 at JMP Securities | 01/14/2025 |
7 | Arvinas, Inc. Reports Q4 Loss, Misses Revenue Estimates | 02/11/2025 |
8 | Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors | 02/24/2025 |
9 | Acquisition by Reid Leonard of 70967 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3 | 02/26/2025 |
10 | Pacira Tops Q4 Earnings Estimates | 02/27/2025 |
11 | Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference | 03/04/2025 |
12 | Werewolf Therapeutics Buy Rating Reiterated at HC Wainwright | 03/12/2025 |
13 | Werewolf Therapeutics Posts Earnings Results, Misses Estimates By 0.03 EPS | 03/13/2025 |
| Begin Period Cash Flow | 155.6 M |
Werewolf |
Werewolf Therapeutics Relative Risk vs. Return Landscape
If you would invest 154.00 in Werewolf Therapeutics on December 24, 2024 and sell it today you would lose (41.00) from holding Werewolf Therapeutics or give up 26.62% of portfolio value over 90 days. Werewolf Therapeutics is currently does not generate positive expected returns and assumes 3.8493% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Werewolf, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Werewolf Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Werewolf Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Werewolf Therapeutics, and traders can use it to determine the average amount a Werewolf Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1129
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HOWL |
Estimated Market Risk
| 3.85 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Werewolf Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Werewolf Therapeutics by adding Werewolf Therapeutics to a well-diversified portfolio.
Werewolf Therapeutics Fundamentals Growth
Werewolf Stock prices reflect investors' perceptions of the future prospects and financial health of Werewolf Therapeutics, and Werewolf Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Werewolf Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (39.04) % | ||||
| Current Valuation | (23.25 M) | ||||
| Shares Outstanding | 44.83 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 26.87 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (51.2 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 10.99 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Earnings Per Share | (1.63) X | ||||
| Market Capitalization | 50.65 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
About Werewolf Therapeutics Performance
By examining Werewolf Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Werewolf Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Werewolf Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.58) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (0.96) | (0.91) |
Things to note about Werewolf Therapeutics performance evaluation
Checking the ongoing alerts about Werewolf Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Werewolf Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics may become a speculative penny stock | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (51.2 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Werewolf Therapeutics Posts Earnings Results, Misses Estimates By 0.03 EPS |
- Analyzing Werewolf Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Werewolf Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Werewolf Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Werewolf Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Werewolf Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Werewolf Therapeutics' stock. These opinions can provide insight into Werewolf Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.63) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.